Your search for ‘Spruson & Ferguson’ returned 1,283 results

Article discusses IP and its relationship with sport and highlights the success of F45 gyms.

Wrap-up of the most notable developments in pharmaceutical patent law in Australia in 2023.

For local technology start-ups, patent protection and a robust patent system are crucial for success in the market.

Harmonisation of patent laws and practices is occurring slowly but surely throughout the world. It follows that the less "idiosyncratic" a country's laws and practices are, the cheaper and easier it should be to obtain patent protection in that country. Harmonisation thereby has potential benefits to Australian patent applicants seeking protection in countries closely aligned with our own patent system.

This decision removes what could have been a significant practical barrier to the Government proving its damages claim.

There is no certainty of PBS damages associated with a pharmaceutical patentee obtaining an interlocutory injunction.

With IP management a core influencer of business and economic performance, Asia is a global innovation powerhouse.

In a potentially dangerous development for patent holders, the Australian Government, in an adventurous move, has accepted the recommendation of the Australian Council on Intellectual Property to introduce an experimental use exemption under the Patents Act.

Australian Advisory Council on Intellectual Property to investigate the innovation patent system

This decision provides clear directions to the Australian Patent Office that AI advances should be readily patentable.

The Examiner's Manual has not been updated to explain the practice change, so it may still be informal at this stage.

The decision clarifies what is needed to receive damages in a claim for unjustified threats of infringement proceedings.

Streamlined extensions are no longer available. How to request an extension of time after 1 April 2021.

in order to have an extension of patent term granted by the Patent Office, a number of requirements need to be satisfied.

In September this year, a bill was passed by the lower house of the French parliament that has the potential to reduce dramatically the cost of obtaining patent protection in Europe. The bill is now to be considered by the French Senate in October and, if approved, it may become law early in 2008. As a result, the cost associated with preparation of translations of a patent may be reduced by as much as 45%.

The initial report included a number of restrictive patent provisions which the government has agreed to accept.

Under the provisions of the TPP Act, manufacturers of tobacco products are required to sell the goods in plain packaging.